Endocrine Pharmacology Practice Questions

Q: Which of the following is a human insulin analog?

Lispro. **Explanation:** Insulin analogs are modified forms of human insulin created using recombinant DNA technology. By altering the amino acid sequence, the pharmacokinetic profile (onset and duration of action) is changed to better mimic physiological insulin secretion. **1. Why Lispro is correct:** **Insulin Lispro** is a **rapid-acting insulin analog**. It is created by reversing the penultimate amino acids on the B-chain (Proline at B28 and Lysine at B27). This modification prevents the formation of hexamers, allowing the insulin to dissociate rapidly into monomers upon subcutaneous injection. This results in a very quick onset (5–15 mins) and a short duration of action, making it ideal for postprandial glucose control. **2. Why the other options are incorrect:** * **Regular Insulin:** This is short-acting **human insulin** (not an analog). It exists as hexamers in solution, requiring 30–60 minutes to dissociate into absorbable monomers. * **NPH (Neutral Protamine Hagedorn):** This is an **intermediate-acting human insulin**. It is a suspension of regular insulin complexed with protamine and zinc to delay absorption. * **Lente Insulin:** This is an intermediate-acting **bovine or porcine insulin** (now largely obsolete). It is a mixture of amorphous and crystalline insulin with zinc. **High-Yield NEET-PG Pearls:** * **Rapid-acting analogs:** Lispro, Aspart, Glulisine (Mnemonic: **L**ive **A**s **G**od). * **Long-acting (Basal) analogs:** Glargine (peakless), Detemir, Degludec (longest half-life). * **Clinical Use:** Rapid-acting analogs have a lower risk of postprandial hypoglycemia compared to Regular insulin because their action profile more closely matches the glucose spike from a meal.

Q: All of the following are true regarding chlorpropamide except?

It is short-acting. **Explanation:** Chlorpropamide is a **first-generation sulfonylurea** used in the management of Type 2 Diabetes Mellitus. **1. Why Option A is the Correct Answer (The Exception):** Chlorpropamide is actually the **longest-acting sulfonylurea**, not short-acting. It has an exceptionally long half-life of approximately **32 to 36 hours**, and its duration of action can extend up to 60 hours. This is due to its high protein binding and slow hepatic metabolism. **2. Analysis of Other Options:** * **Option B (Hypoglycemia in elderly):** Because of its long half-life and renal excretion, chlorpropamide carries a very high risk of **prolonged hypoglycemia**, especially in elderly patients with declining renal function. It is generally avoided in this population. * **Option C (Weight gain):** Like all sulfonylureas, chlorpropamide stimulates insulin release (an anabolic hormone), which typically leads to weight gain as a common side effect. * **Option D (Alcoholic flush):** Chlorpropamide is notorious for causing a **Disulfiram-like reaction** (facial flushing, tachycardia) when consumed with alcohol. It inhibits hepatic aldehyde dehydrogenase, leading to acetaldehyde accumulation. **High-Yield Clinical Pearls for NEET-PG:** * **SIADH:** Chlorpropamide is unique among sulfonylureas because it increases the action of ADH on renal tubules, potentially causing **dilutional hyponatremia** (SIADH-like effect). * **Mechanism:** It acts by closing ATP-sensitive K⁺ channels in pancreatic beta cells, leading to depolarization and insulin release. * **Safety:** Due to the risks of severe hypoglycemia and water retention, it has largely been replaced by second-generation sulfonylureas (e.g., Glipizide, Gliclazide) in modern practice.

Q: What is the half-life of intravenous oxytocin?

3 minutes. Oxytocin is a peptide hormone synthesized in the hypothalamus and released by the posterior pituitary. When administered intravenously, it has a **very short half-life of approximately 3 to 5 minutes** [1]. This rapid clearance occurs because oxytocin is quickly degraded by the enzyme **oxytocinase** (aminopeptidase), which is produced by the placenta and found in the liver and kidneys [1]. This short half-life is clinically significant as it allows for precise titration during labor induction; if uterine hyperstimulation occurs, stopping the infusion leads to a rapid decline in plasma levels and cessation of effect within minutes. Also, oxytocin acts through G protein-coupled receptors to contract uterine smooth muscle [1].

Q: What is the major adverse effect of glucocorticoids, especially in children?

Posterior subcapsular cataract. **Explanation:** Glucocorticoids have widespread systemic effects, and their ocular toxicity is a high-yield topic for NEET-PG. **Why Option D is Correct:** **Posterior subcapsular cataract (PSC)** is a classic and major adverse effect of long-term glucocorticoid therapy. While it can occur in adults, **children are significantly more susceptible** to this complication. The mechanism involves the binding of steroids to lens proteins, leading to protein aggregation and lens opacification. Unlike steroid-induced glaucoma (which may resolve), steroid-induced cataracts are usually **irreversible** and often require surgical intervention. **Analysis of Incorrect Options:** * **A. Hyperkalemia:** Glucocorticoids have inherent mineralocorticoid activity (especially cortisol and prednisolone), which promotes sodium retention and potassium excretion. Therefore, they cause **hypokalemia**, not hyperkalemia. * **B. Hypoglycemia:** Glucocorticoids are "diabetogenic." They stimulate gluconeogenesis and decrease peripheral glucose uptake, leading to **hyperglycemia** (Steroid-induced Diabetes). * **C. Muscular weakness:** While "Steroid Myopathy" does occur due to muscle wasting (proteolysis), it typically affects the **proximal** muscles of the limbs. However, in the context of pediatric-specific major adverse effects, PSC is a more distinct and frequently tested ocular complication. **NEET-PG High-Yield Pearls:** * **Ocular triad of steroids:** Posterior subcapsular cataract, increased intraocular pressure (glaucoma), and secondary ocular infections (fungal/viral). * **Growth Suppression:** In children, the most significant systemic concern is the suppression of the **growth plate** and GH inhibition, leading to stunted growth. * **Alternate-day therapy:** This strategy is often used in children to minimize growth suppression and HPA-axis suppression.

Q: Hypokalemic paralysis is a side effect of which of the following?

Gossypol. **Gossypol** is a polyphenolic compound derived from the cotton plant (*Gossypium*) used as a male oral contraceptive. Its primary mechanism involves inhibiting sperm motility and spermatogenesis by interfering with mitochondrial enzymes and lactate dehydrogenase-X [1]. **Why Gossypol is the correct answer:** The most significant and clinically relevant side effect of Gossypol is **hypokalemia**, which can lead to **hypokalemic periodic paralysis** [1]. This occurs because Gossypol causes renal potassium wasting by inhibiting the Na+-K+ ATPase pump and affecting renal tubular function. This side effect is often irreversible in a small percentage of users, which has limited its clinical adoption as a mainstream contraceptive [1]. **Analysis of Incorrect Options:** * **B. DMPA (Depot Medroxyprogesterone Acetate):** An injectable progestogen-only contraceptive. Common side effects include weight gain, menstrual irregularities, and a reversible decrease in bone mineral density (BMD), but not hypokalemia. * **C. Testosterone enanthate:** An androgen used for replacement therapy or male contraception. Side effects include acne, erythrocytosis (increased hematocrit), and suppression of HDL; it does not cause potassium depletion. * **D. Cyproterone acetate:** An anti-androgen with progestogenic activity. It is used in treating hirsutism and prostate cancer. Its main side effects include hepatotoxicity and fatigue, not hypokalemic paralysis. **High-Yield Clinical Pearls for NEET-PG:** * **Gossypol's "Rule of 3":** It causes **Hypokalemia**, **Irreversibility** (in 10-20% of cases), and **Infertility**. * **Mechanism:** It acts as a non-hormonal male contraceptive. * **Other side effects:** Edema and digestive disturbances. * **Note:** Due to the risk of permanent infertility and life-threatening hypokalemia, it is currently not FDA-approved.

Q: In a patient on long-term steroid therapy, what precaution should be taken prior to tooth extraction?

Administer additional steroids. **Explanation:** The correct answer is **Administer additional steroids** (Option B). **1. Why it is correct:** Patients on long-term steroid therapy (typically >5 mg prednisolone equivalent for >2 weeks) experience **Hypothalamic-Pituitary-Adrenal (HPA) axis suppression**. Under normal conditions, the body increases cortisol production during physical stress (like surgery or trauma) to maintain hemodynamic stability. In these patients, the suppressed adrenal glands cannot produce this "stress dose" of cortisol, putting the patient at risk of a life-threatening **Adrenal Crisis** (acute hypotension, shock, and collapse). Therefore, supplemental "stress doses" of steroids are required prior to stressful procedures like tooth extraction. **2. Why other options are incorrect:** * **Option A:** Stopping steroids is dangerous as it can precipitate withdrawal symptoms and immediate adrenal crisis. * **Option C:** While antibiotics may be used to prevent infection in immunocompromised patients, they do not address the physiological risk of adrenal insufficiency. * **Option D:** Continuing the usual dose is insufficient because the baseline dose does not account for the increased metabolic demand required to handle surgical stress. **3. High-Yield Clinical Pearls for NEET-PG:** * **Rule of Twos:** HPA suppression should be suspected if a patient has taken **20 mg** of prednisone (or equivalent) for **2 weeks**, within the last **2 years**. * **Dosing:** For minor oral surgery (e.g., simple extraction), a common regimen is 5–10 mg of prednisolone or 25 mg of hydrocortisone pre-operatively. * **Steroid Potency:** Remember the potency ratio for exams: **Hydrocortisone (1) < Prednisolone (4) < Dexamethasone (25).** * **Adrenal Crisis Presentation:** Unexplained hypotension that does not respond to fluids or vasopressors but responds to IV hydrocortisone.

Q: All of the following statements about alpha-glucosidase inhibitors are true EXCEPT?

Hypoglycemia is a common and serious side effect. **Explanation:** Alpha-glucosidase inhibitors (AGIs), such as **Acarbose, Miglitol, and Voglibose**, act by reversibly inhibiting the enzyme alpha-glucosidase in the brush border of the small intestine. This enzyme is responsible for breaking down complex polysaccharides into absorbable monosaccharides (glucose). **Why Option C is the correct answer (The False Statement):** AGIs do not stimulate insulin secretion; they merely delay glucose absorption. Therefore, when used as **monotherapy, they do not cause hypoglycemia**. However, if hypoglycemia occurs because of concurrent use with sulfonylureas or insulin, it must be treated with **pure glucose (dextrose)** and not sucrose (cane sugar), as AGIs will block the breakdown and absorption of sucrose. **Analysis of other options:** * **Option A:** This is the primary mechanism. By delaying the digestion of carbohydrates, AGIs reduce post-prandial glucose excursions. * **Option B:** While primarily used in Type 2 Diabetes, AGIs can be used as an adjunct in Type 1 Diabetes to smooth out post-meal glucose spikes. * **Option C:** AGIs are frequently combined with Metformin, Sulfonylureas, or Insulin to achieve better glycemic control. **High-Yield NEET-PG Pearls:** * **Side Effects:** The most common side effects are GI-related (flatulence, diarrhea, abdominal bloating) due to the fermentation of undigested carbohydrates by colonic bacteria. * **Contraindications:** Inflammatory Bowel Disease (IBD), intestinal obstruction, or chronic intestinal diseases. * **Voglibose:** Often preferred over Acarbose due to a better side-effect profile (less flatulence). * **Clinical Utility:** Best suited for patients with high **post-prandial hyperglycemia**.

Q: Glucose intolerance is seen with all the following medications except?

ACE inhibitors. **Explanation:** The correct answer is **ACE inhibitors (Option C)**. Unlike the other drugs listed, ACE inhibitors (and ARBs) actually **improve insulin sensitivity** and are considered renoprotective in diabetic patients. They increase levels of bradykinin, which enhances glucose uptake in skeletal muscles, and improve pancreatic blood flow, thereby reducing the risk of new-onset type 2 diabetes. **Why the other options are incorrect:** * **Thiazide Diuretics (A):** These are notorious for causing hyperglycemia. They inhibit insulin release from the pancreas (partly due to hypokalemia, as insulin secretion is K+ dependent) and decrease peripheral glucose utilization. * **Beta Blockers (B):** Non-selective beta-blockers (like Propranolol) inhibit $\beta_2$-mediated insulin release and decrease peripheral insulin sensitivity. Crucially, they also mask the autonomic warning symptoms of hypoglycemia (tachycardia, tremors), making them risky for diabetics. * **Phenytoin (D):** This anticonvulsant directly inhibits the release of insulin from the pancreas, leading to "Phenytoin-induced hyperglycemia." **High-Yield Clinical Pearls for NEET-PG:** 1. **Drugs causing Hyperglycemia (Glucose Intolerance):** Remember the mnemonic **"S-P-I-T"**: **S**teroids, **P**henytoin/Protease Inhibitors, **I**mmunosuppressants (Tacrolimus/Cyclosporine), and **T**hiazides. 2. **Atypical Antipsychotics:** Olanzapine and Clozapine carry the highest risk of metabolic syndrome and new-onset diabetes. 3. **Statins:** While beneficial for cardiovascular health, high-dose statins are associated with a slight increase in the risk of developing type 2 diabetes. 4. **Drug of Choice:** ACE inhibitors are the preferred antihypertensives in diabetic patients with proteinuria/albuminuria.

Q: Which drug inhibits the binding of RANKL to its receptor (RANK) in osteoporosis?

Denosumab. **Explanation:** **Denosumab** is a fully human monoclonal antibody that targets and binds to **RANKL** (Receptor Activator of Nuclear Factor kappa-B Ligand). Under normal physiological conditions, RANKL is secreted by osteoblasts and binds to RANK receptors on osteoclast precursors, triggering their maturation and activation. By inhibiting this binding, Denosumab prevents osteoclast formation and activity, thereby decreasing bone resorption and increasing bone mineral density (BMD). **Analysis of Incorrect Options:** * **A. Teriparatide:** A recombinant formulation of PTH (1-34). Unlike other agents, it is **anabolic**; it stimulates osteoblastic activity and new bone formation when given in intermittent pulses. * **B. Alendronate:** A **Bisphosphonate**. It works by depositing into the bone matrix and inducing apoptosis of osteoclasts once they ingest the drug. It does not interfere with the RANKL-RANK pathway directly. * **C. Estrogen:** Reduces bone resorption by suppressing the transcription of bone-resorbing cytokines (like IL-1, IL-6, and TNF) and increasing the production of **Osteoprotegerin (OPG)**, a natural decoy receptor for RANKL. **High-Yield NEET-PG Pearls:** * **Denosumab Administration:** Given as a subcutaneous injection once every 6 months. * **Osteoprotegerin (OPG):** Denosumab essentially mimics the physiological function of OPG. * **Side Effects:** Denosumab is associated with an increased risk of infections (due to RANKL's role in the immune system) and, rarely, osteonecrosis of the jaw (ONJ). * **Drug of Choice:** Bisphosphonates remain the first-line treatment for most osteoporosis cases; Denosumab is often reserved for patients with renal impairment or those who fail bisphosphonate therapy.

Question 1

Which of the following is a human insulin analog?

Accepted Answer

Lispro

Answer

Regular

Answer

NPH insulin

Answer

Lente insulin

Question 2

All of the following are true regarding chlorpropamide except?

Accepted Answer

It is short-acting

Answer

It can cause hypoglycemia in the elderly

Answer

Causes weight gain

Answer

Associated with alcoholic flush

Question 3

What is the half-life of intravenous oxytocin?

Accepted Answer

3 minutes

Answer

30 minutes

Answer

3 hours

Answer

45-60 minutes

Question 4

What is the major adverse effect of glucocorticoids, especially in children?

Accepted Answer

Posterior subcapsular cataract

Answer

Hyperkalemia

Answer

Hypoglycemia

Answer

Muscular weakness

Question 5

Which one of the following does NOT act by increasing insulin secretion?

Accepted Answer

Biguanide

Answer

Glyburide

Answer

Repaglinide

Answer

Tolbutamide

Question 6

Hypokalemic paralysis is a side effect of which of the following?

Accepted Answer

Gossypol

Answer

DMPA

Answer

Testosterone enanthate

Answer

Cyproterone acetate

Question 7

In a patient on long-term steroid therapy, what precaution should be taken prior to tooth extraction?

Accepted Answer

Administer additional steroids

Answer

Stop steroids before extraction

Answer

Increase antibiotic coverage

Answer

Continue steroids as usual

Question 8

All of the following statements about alpha-glucosidase inhibitors are true EXCEPT?

Accepted Answer

Hypoglycemia is a common and serious side effect

Answer

Reduces intestinal absorption of carbohydrates

Answer

Effective in both type 1 and type 2 diabetes

Answer

Can be used with other oral hypoglycemic agents

Question 9

Glucose intolerance is seen with all the following medications except?

Accepted Answer

ACE inhibitors

Answer

Thiazide diuretics

Answer

Beta blockers

Answer

Phenytoin

Question 10

Which drug inhibits the binding of RANKL to its receptor (RANK) in osteoporosis?

Accepted Answer

Denosumab

Answer

Teriparatide

Answer

Alendronate

Answer

Estrogen

Endocrine Pharmacology — MCQs

Endocrine Pharmacology — MCQs

On this page

Practice by Chapter

Want unlimited practice?